The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! About 1.81 million shares traded hands. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 43.85% since April 8, 2016 and is downtrending. It has underperformed by 49.50% the S&P500.
The move comes after 8 months positive chart setup for the $673.31M company. It was reported on Nov, 10 by Barchart.com. We have $6.20 PT which if reached, will make NASDAQ:ACHN worth $208.73M more.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage
Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. Achillion Pharma has been the topic of 15 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Wedbush initiated it with “Outperform” rating and $13 target price in Friday, September 23 report. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Buy” rating given on Tuesday, September 8 by UBS. Jefferies initiated the stock with “Hold” rating in Wednesday, September 9 report. The company was downgraded on Friday, January 29 by Leerink Swann. On Friday, September 23 the stock rating was maintained by Chardan Capital Markets with “Sell”. The firm has “Market Perform” rating given on Wednesday, May 4 by Leerink Swann. As per Thursday, September 15, the company rating was initiated by FBR Capital. The company was maintained on Thursday, August 13 by Maxim Group. The stock has “Neutral” rating given by Chardan Capital Markets on Friday, November 4. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Market Outperform” rating by JMP Securities on Thursday, July 7.
According to Zacks Investment Research, “ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.08, from 0.92 in 2016Q1. The ratio improved, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
Nationwide Fund Advisors has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Manufacturers Life Ins The owns 80,401 shares or 0% of their US portfolio. Moreover, Prtn Ltd Liability Co has 0.18% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 285,600 shares. Legal General Public Limited Com has 0% invested in the company for 18,010 shares. Blackrock Institutional Company Na reported 3.02 million shares or 0% of all its holdings. Next Fincl Group Incorporated holds 200 shares or 0% of its portfolio. Moreover, Balyasny Asset Management Ltd Limited Liability Company has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 23,100 shares. New York State Common Retirement Fund last reported 0% of its portfolio in the stock. Moreover, Rhenman Prtn Asset has 0.37% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 266,000 shares. Blair William Il has 0% invested in the company for 37,400 shares. Dekabank Deutsche Girozentrale holds 0.01% or 70,300 shares in its portfolio. Blackrock Mngmt Lc accumulated 437,200 shares or 0% of the stock. Amalgamated Retail Bank has 12,379 shares for 0.01% of their US portfolio. Connor Clark & Lunn Inv Management Ltd accumulated 0.05% or 843,947 shares. California State Teachers Retirement Systems, a California-based fund reported 246,060 shares.
ACHN Company Profile
Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.